Skip to Content
MDPIMDPI

Advanced

PharmaceuticalsPharmaceuticals
PDF
  • Review
  • Open Access

27 February 2026

14 Pages

SGLT1 and SGLT2 Modulation in Antidiabetic Therapy—Comparative Insights into Gliflozins and Natural Compounds Resveratrol and Viniferin

,
,
,
,
,
and
Faculty of Veterinary Medicine, University of Life Sciences “King Mihai I” from Timisoara, 300645 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Pharmaceuticals2026, 19(3), 376;https://doi.org/10.3390/ph19030376
This article belongs to the Section Biopharmaceuticals
Version Notes
Order Reprints

Abstract

Glucose transport dysregulation plays a central role in pathophysiology of diabetes mellitus. Synthetic agents like sotagliflozin or canagliflozin have been discovered recently and are currently used as antidiabetic therapy, providing great efficacy in modulation of glucose transport. However, the search for additional compounds with antidiabetic potential continues, as researchers aim to identify new molecules that may complement or enhance existing therapies. Numerous plant-derived compounds are currently under investigation and have demonstrated promising effects, while others remain far less studied yet could hold meaningful potential. In this context, resveratrol and its oligomers, including ε-viniferin, have gained attention due to promising in vitro findings, particularly due to influencing glucose homeostasis through direct SGLT interaction, indirect metabolic pathways, or a combination of both. This review examines their molecular mechanisms, absorption profiles, and inhibitory activity on sodium–glucose cotransporters SGLT1 and SGLT2. While resveratrol demonstrates high cellular uptake and metabolic conversion, ε-viniferin exhibits poor intestinal permeability, suggesting limited systemic bioavailability but potential local activity at the intestinal epithelium. Gliflozins are clinically validated dual SGLT1/SGLT2 inhibitors that offer superior glucose-lowering efficacy and organ protection. In regard to stilbenoids, they offer promising in vitro results, though in vivo studies and clinical trials are scarce. Understanding resveratrol and viniferin pharmacokinetics, target interactions, and limitations is vital for their development as potential complementary or even alternative antidiabetic therapies.

1. Introduction

The global rise in diabetes mellitus presents a major public health challenge in humans but also in animals. It is estimated that, in Europe, 1.2% of dogs and 0.4% of cats will develop diabetes during their lifetime [1]. According to the International Diabetes Federation, more than 9% of people are currently diagnosed with diabetes in Europe [2]. Type 2 diabetes is considered to be the most prevalent form [3]. Although insulin secretion in affected individuals may range from deficient to excessive, the hormone is rendered ineffective by impaired tissue responsiveness [4]. At the same time, diabetes is one of the leading causes for cardiovascular and renal diseases—cardiovascular complications being the primary cause of mortality in the population suffering from this metabolic disease [3].
Modulating peripheral glucose metabolism by inhibition of intestinal absorption or by enhancement of renal glucose excretion, while employing counterregulatory mechanisms to restore metabolic balance, may present a promising approach for glycemic control [5]. SGLT1/2 inhibitor drugs like gliflozins (canagliflozin, sotagliflozin, dapagliflozin, empagliflozin, ertugliflozin) have recently been approved as a novel class of glycemic control agents [5]. These synthetic compounds are currently used for the treatment of diabetes mellitus, with proven effectiveness in managing this metabolic disease, while also offering additional benefits. Side effects are a common feature of synthetic drugs, in line with other medicinal agents; however, in case of gliflozins, their clinical benefits often outweigh these limitations [6,7,8].
Alongside synthetic drugs, plant-derived bioactive compounds like quercetin, kaempferol, epigallocatechin gallate, resveratrol and viniferin are gaining recognition in biomedical research. Amongst those, certain compounds are well studied, whereas others are comparatively under-investigated. Included in the latter category are resveratrol and viniferin, which offer a promising reservoir of compounds capable of selectively modulating intestinal and renal glucose transporters. Recent studies show that these molecules and their isoforms inhibit SGLT1 and/or SGLT2 glucose cotransporters [9,10,11,12,13]. In the literature, besides antidiabetic properties, numerous other beneficial effects of these compounds are mentioned [13,14].
This review aims to summarize and report the currently available findings on the inhibitory effects of resveratrol and viniferin with interest towards their therapeutic roles. While gliflozins are synthetic SGLT inhibitors already established as effective treatments for diabetes mellitus, we aim to underscore the possibility that these plant-derived compounds could, with further translational research, evolve into effective therapeutic options for diabetes management.

2. Materials and Methods

2.1. Literature Search Strategy

A comprehensive literature search was conducted across major scientific databases, including PubMed, Scopus, and Web of Science, using keywords such as “resveratrol”, “viniferin”, “SGLT1”, “SGLT2”, “gliflozin” and “glucose transport” in combination with “mechanism”, “structure” and “diabetes therapy”. Peer-reviewed articles published between 2000 and 2024 were screened for relevance based on predefined inclusion criteria focusing on molecular interactions, transporter biology, and pharmacological applications.

2.2. AI-Enhanced Analysis

Throughout the development of this review article, Windows AI assistant Copilot contributed to the synthesis of complex scientific literature by providing tailored summaries of research findings and conceptual overviews. Through the AI-assisted tool, the experimental designs and key insights were extracted. These contributions were guided and verified by the authors to ensure scientific accuracy and relevance, making the AI-assisted process both efficient and rigorously human-curated.

2.3. Operational Flow

Zotero was employed as a dedicated reference management tool to organize, annotate, and streamline the citation process. By facilitating the efficient collection of peer-reviewed articles and research data from multiple databases, Zotero enabled consistent documentation and cross-referencing of sources throughout the manuscript. Its integration with word processing software ensured precise in-text citations and a dynamically generated bibliography aligned with journal formatting guidelines.
This tool played a central role in maintaining scholarly rigor and traceability of the literature discussed.

2.4. Data Extraction and Validation

Data extraction involved cataloging findings related to resveratrol and viniferin structures and mechanisms of action, SGLT transporter function, and therapeutic outcomes in clinical and preclinical models.
To streamline analysis and improve consistency, AI-assisted tools were employed for text summarization, semantic mapping, and synthesis of key concepts across sources. These enhancements ensured rapid identification of thematic trends and cross-study comparisons. All AI-generated content was rigorously reviewed and validated by human oversight.
Through the fusion of AI-enhanced screening tools and expert assessment, this review rigorously explored the molecular frameworks of SGLT1/2, the pathways by which resveratrol and viniferin regulate glucose homeostasis, as well as antidiabetic therapeutic insights.

3. Results and Discussions

3.1. Sodium–Glucose Cotransporters in the Intestine and Kidney

3.1.1. SGLT1

SGLT1 is a 664 amino acid membrane protein with 14 transmembrane α helices and both termini located extracellularly. Its C-terminal domain (TM10–TM14) contains two sugar-binding sites. The external binding site likely represents the high-affinity site, while the internal binding site might be the low-affinity site [15].
This protein is highly expressed on the brush border membrane of enterocytes in the small intestine, where it mediates glucose absorption. It is also present in the kidney (S2 [16] and S3 [17] segments), and has been detected in salivary glands and the heart [17].
Research shows that expression of this protein in the intestine increases with high glucose diets [18,19,20] and after luminal glucose infusion [18,19]. It has been reported that in mice, 24–48 h fasting enhances SGLT1 activity in the intestine [21]. Segment-specific studies done by Klinger and Breves (2018) show higher electrogenic glucose transport in the ileum compared to the jejunum, despite similar or lower SGLT1 protein levels [22].
The SGLT1 transport mechanism is described as a secondary active transport that uses the sodium gradient—maintained by the Na+/K+-ATPase pump— to facilitate glucose uptake. SGLT1 protein cotransports one D-glucose molecule together with two sodium ions into the cell [23,24]. The transport process involves firstly the binding of the two sodium ions to the protein, which increases the transporters’ affinity for glucose [15,23]. As a repercussion, one glucose molecule binds to the transporter. This event triggers conformational changes that will result in translocation of the glucose molecule, followed by that of the two sodium ions. SGLT1 then suffers another conformational change which allows the protein to expose the sodium- and glucose-binding sites towards the luminal side. Wright et al. (2004) mention that SGLT1 can recycle approximately 1000 times per second at 37 °C [15]. The sodium-dependent glucose transporter SGLT1 in the small intestine is characterized by low capacity and high affinity [15], as the approximate value of the substrate concentration at which the reaction rate reaches half of its maximum velocity is Km = 0.5 mM for D-glucose [23]. One study reports that, in humans, glucose Km is 2 mM/L for SGLT1 [15].
  • In the literature, it is mentioned that the regulation of SGLT1 involves sweet taste receptors T1R2/T1R3 found on enteroendocrine cells, which activate a signaling cascade that leads to: increasing of enterocyte cAMP levels, stabilization of SLC5A1 mRNA, and upregulated insertion of SGLT1 into the apical membrane [19,25].
  • Regulation of the SGLT1 transporter, as Sabino-Silva et al. (2010) describe, occurs through protein kinases through either: the direct pathway which implies the β-adrenoreceptors; the indirect regulation described as the modifications tied to the insertion and retrieval of the SGLT1 protein into the plasma membrane [17].
Other molecules transported by SGLT1, besides glucose, are D-galactose [23] and water [15,17,26]. Two distinct mechanisms have been reported regarding water absorption through SGLT1:
Cotransport of 200–260 water molecules per cycle with Na+ and glucose [17,26];
Passive water/urea flow through channels formed by the C-terminal C5 domain [27].

3.1.2. SGLT2

The gene that is responsible for encoding the sodium-dependent glucose transporter SGLT2 is SLC5A2 [17,28]. This protein is found mainly in the kidneys, namely in the initial segments of the proximal renal tubule [17]. In mouse kidneys, Park et al. (2018), cited by Ghezzi et al. (2018), report that in single-cell RNA sequencing experiments, SGLT2 is specifically and uniquely active in cells of the S1 tubular segment [28]. In man and mice, HNF-1α seems to directly control the renal expression of SGLT2 [29]. In diabetic rats, it is reported that both the level of SGLT2 and HNF-1α mRNA expression is 50% higher [30]. SGLT2 is also expressed in other tissues like intestine, liver, mammary glands, lungs, skeletal muscle, and spleen [17].
SGLT2 protein is made up of 672 amino acids. Structurally, this protein exhibits two termini, NH2 and COOH, which are positioned extracellularly [17]. The stoichiometry of SGLT2 is 1:1, namely one sodium ion is transported along one glucose molecule. Even though in this transporters’ structure two sodium-binding sites are present, the region where the second sodium ion would attach (Na3) is occluded [31].
Hiraizumi et al. (2024), using cryo-electron microscopy, revealed the outward-facing and inward-open structures of the human SGLT2 transporter during glucose transport [31]. The authors report that SGLT2 movement follows the alternating-access mechanism, while also mentioning its two components:
  • the immobile fraction provides a fixed frame, made up of transmembrane helices: TM1, TM2, TM6, TM7, TM11, TM12 and TM13; this structure includes the bundle domain, which offers an anchor point for conformational changes during glucose transport, and, as the same researchers state, it is made up of transmembrane helices: TM1, TM2, TM6, TM7. Mentioned is also the protein MAP17, which aligns closely to TM13 stabilizing the bundle domain and the hash domain that rotates around the sodium-binding site, regulating the inward- and outward-facing conformations of SGLT2 [31].
  • the mobile component is made up of transmembrane helices: TM0, TM3, TM4, TM5, TM8, TM9 and TM10; inward-open and outward-facing conformations are determined by movement of the gate helices, namely: TM5, TM10 [31].
SGLT2 is known to mediate the reabsorption of more than 90% of glucose from the kidney filtrate; however, its detailed functional characterization remains relatively limited [15,32]. In the last decade, studies regarding this domain have emerged, as whole-cell patch-clamp electrophysiology experiments on embryonic kidney 293T cells show a similar affinity for D-glucose of both SGLT1 and SGLT2 under physiological conditions in the straight proximal tubule [32], despite the classical view of SGLT1 as a high-affinity, low-capacity transporter and SGLT2 as a low-affinity, high-capacity one [15].
Hummel et al. (2011) indicate that when glucose transport is saturated, the maximum current can be recorded (Imax), while charge movements before transport starts are attributed to the pre-steady-state currents (Qmax) [32]. The researchers underlined that SGLT1 seems to have a 10 times greater Imax value than that of SGLT2, and that no Qmax was detected in SGLT2. The findings suggest that the two transporters differ fundamentally in their kinetic behavior, turnover, or membrane abundance, though it is unclear if the results obtained are due to greater copy numbers of the transporter, to a higher turnover rate, or both [32].

3.2. Inhibitors of Sodium–Glucose Cotransporters SGLT1 and SGLT2

In 1999 phlorizin, a natural compound extracted from apple bark was used in streptozotocin-induced diabetic rats. As a result, blood glucose levels decreased rapidly, with glucose being excreted through the urine. This natural compound was the first agent discovered to competitively inhibit SGLT1 and SGLT2 [5,33]. Glucoside is described as a specific, high-affinity, competitive inhibitor of sodium–glucose cotransporters 1 and 2. Phlorizin is made up of a glucose-like structure which binds to the SGLT C-terminal domain and a phloretin tail, which binds to an ectodomain, stabilizing the transporter in a non-functional state, therefore preventing structural changes that could lead to glucose transport [34]. Phlorizin is not transported across the membrane of the cells, it remains bound to the SGLT domain. Being a competitive inhibitor, at a certain luminal glucose concentration it is possible for this compound to be dislodged from the binding site [15,35]. Phlorizin is a potent inhibitor of SGLT1 and SGLT2, but certain adverse effects were also noted, as oral administration is associated with diarrhea and gastrointestinal disturbances [36], therefore limiting its clinical use.
In recent years, pharmacological inhibition of SGLT transporters has emerged as a therapeutic strategy for patients with Type 1 and 2 diabetes mellitus. SGLT1/2 synthetic inhibitors, including canagliflozin, dapagliflozin, empagliflozin and sotagliflozin, have shown great results in lowering blood glucose levels and promoting glucose excretion [37,38,39,40,41,42]. Their efficacy and safety are supported by extensive human trials [5,6,43,44]. Some studies report adverse effects during in vivo treatment with gliflozins [36,45]. However, Mulani et al. (2025) mention that even through there are certain side effects that might occur when gliflozins are administered, they are generally well-tolerated [8], and even provide additional benefits [6,7,8,46].
Gliflozins are currently used as a first-line treatment for diabetes, yet researchers continue to search for new therapeutic compounds. Increasing attention has turned toward plant-derived molecules, particularly those capable of modulating glucose homeostasis. These natural agents may directly inhibit SGLT transporters, indirectly influence them through metabolic signaling pathways, or in some cases combine both mechanisms [14,47,48,49,50]. Some of those plant-based substances are flavanones like (-)-kurarinone or sophoraflavanone G extracted from Sophora flavescens, indole alkaloids like alstiphyllanine D or 10-methoxy-N(1)-methylburnamine-17-O-veratrate extracted from Alstonia macrophylla and stilbenoids like viniferin and resveratrol extracted from Vitis vinifera [51]. Within this diverse group, resveratrol and its oligomeric derivative viniferin remain comparatively less studied, although several reports have examined their potential antidiabetic effects, while most of the available evidence is largely based on in vitro experiments. Their mechanism of action differs from that of gliflozins, highlighting the need to further investigate how these polyphenols influence glucose homeostasis. According to current research, these plant-derived polyphenols influence glucose homeostasis through various pathways: modulation of intracellular signaling, membrane interactions, and localized intestinal effects [10,11,47,52,53].
Assessment of the inhibitory effect of certain compounds towards SGLT1 and SGLT2 activity can be done through a number of techniques. Most research assessments are done via in vitro methods, while direct in vivo inhibition of SGLT1/SGLT2 by viniferin or resveratrol is not yet conclusively demonstrated [11,54,55]. However, the anti-hyperglycemic and anti-hyperlipidemic potential of these compounds is evaluated through blood glucose assessments, insulin levels, glucose transporters expression, total cholesterol, triglyceride value, low-density lipoprotein-cholesterol value and glucose tolerance tests [47]. In Table 1, methods used to assess the inhibitory activity of gliflozins, resveratrol, viniferin (or their isomers) on SGLT1 and/or SGLT2 transporters can be seen.
Table 1. Methods used for assessment of gliflozins’, resveratrol’s or viniferin’s inhibitory effect on SGLT1/2.
Resveratrol, also known as 3,5,4′-trihydroxy-trans-stilbene, is a phenolic compound that is produced by plants as a defense mechanism in response to certain stressors: microbial attack, toxins, infections or UV radiation [11]. First isolated in 1940, it is known to be abundant in grape skins, where the trans-isomer predominates and shows the highest stability and biological activity [59]. Its bioavailability is generally low, although encapsulation strategies (e.g., yeast, liposomes) can improve stability and absorption [55].
Absorption of resveratrol in the intestine occurs through diffusion or by forming complexes with certain membrane transporters [48]. Another possible pathway is transmembrane transport of resveratrol via raft-dependent endocytosis [22]. Biophysical studies show that resveratrol localizes near the interface of the hydrophilic headgroups and hydrophobic core of the lipid bilayer, which may contribute to its membrane-associated regulatory effects [60,61]. However, unlike gliflozins, its interaction with glucose transport seems to be indirect. In Ussing chamber experiments, resveratrol reduced glucose-induced short-circuit currents, suggesting decreased SGLT1-mediated glucose absorption [22], yet the evidence points towards regulatory effects, not direct transporter inhibition [10,22]. Studies attribute these changes to intracellular signaling pathways—such as AMPK activation—or to adaptive SGLT1 phosphorylation, rather than a direct binding interaction with the transporter [10]. To date, we could not find any molecular data that demonstrate direct competitive inhibition of SGLT1 by resveratrol. Most inhibitory effects of resveratrol reported in the literature arise from systemic actions [48,62,63].
After absorption, resveratrol binds to albumins and lipoproteins, which act as carriers and facilitate tissue uptake [62]. This compound has been detected in vascular tissues for up to 24 h after oral administration, and one study reports interactions with endothelial SGLT1, though the functional significance remains unclear [63]. Beyond glucose transport modulation, there are other benefits associated with resveratrol administration [64].
When resveratrol molecules undergo coupling through phenoxyl radical intermediates—a process first proposed by Langcake and Pryce (1977)—oligomeric forms of the compound are generated [11]. The bond can form at different positions on the aromatic rings, resulting in region-isomers. The molecules that are formed are structurally similar but spatially distinct dimers. One of those molecules is viniferin. Amongst the forms of viniferin mentioned are α-viniferin, β-viniferin, ε-viniferin, δ-viniferin, γ-viniferin, vitisin A and vitisin B [11]. Structurally, viniferin is rich in carbon and hydrogen, making it poorly water-soluble and highly sensitive to UV light. More than 90% of trans-ε-viniferin converts to its cis-form within 30 min of UVA exposure, after which it degrades into less active phenanthrenes. This degradation process happens in other stilbenes, such as resveratrol [65].
In vitro studies show that ε-viniferin is minimally absorbed across the intestinal epithelium. Ex vivo experiments using porcine jejunum and ileum demonstrate that ε-viniferin reduces glucose-induced short-circuit currents, indicating inhibition of SGLT1-mediated electrogenic glucose transport [52]. However, direct binding to SGLT1 has not been conclusively demonstrated. Additional evidence from murine-everted gut sacs shows that 0.1 mM ε-viniferin reduces α-methyl-glucopyranoside uptake by 50%, and data suggest a non-reversible inhibitory effect [54]. One proposed mechanism is that ε-viniferin interacts with membrane phospholipids, rather than binding directly to the transporter [34,54]. However, molecular docking studies suggest that ε-viniferin potentially blocks glucose access to SGLT2 [66].
In vivo studies indicate broader metabolic benefits associated with viniferin administration. Mechanistically, ε-viniferin interacts with AMP-activated protein kinase (AMPK), binding residues in both α- and β-subunits, suggesting a role in AMPK activation and improved metabolic regulation. The lack of side effects observed during the mentioned study could suggest a favorable tolerability of this compound at doses up to 60 mg/kg [47]. Studies report additional antilipidemic effects [14,47].
Table 2 shows a summary of synthetic gliflozins and natural compounds resveratrol and viniferin specification.
Table 2. Summary of synthetic gliflozins and natural compounds resveratrol and viniferin specifications.

4. Conclusions

SGLT1 is expressed mainly in the small intestine, while SGLT2 is mostly expressed in the renal tubule. There are several factors that influence the level of their expression.
The sodium-dependent glucose-active transport mediated by SGLT1 and SGLT2 involves a multitude of cellular mechanisms. A better understanding of those proteins’ functional role might offer certain clinical insights regarding their modulation.
Phlorizin, while the first natural inhibitor of SGLT1/2 discovered, has limited clinical applicability.
Gliflozins represent a major advancement in antidiabetic therapy, offering selective SGLT1/2 inhibition with proven efficacy in glycemic control and cardiovascular protection.
Viniferin and resveratrol offer natural, multi-targeted support in diabetes and other metabolic states related to diabetes. The mechanisms involved in glucose regulation mediated by stilbenoids are complex. SGLT’s direct inhibitory mechanism is yet to be subjected to further studies. While resveratrol and viniferin inhibition of glucose uptake is supported by functional data, molecular studies that explicitly characterize the direct inhibitory interaction between those polyphenols and SGLT are necessary.
Comparative analysis between synthetic gliflozins and the natural compounds viniferin and resveratrol reveals certain advantages and limitations regarding their use as antidiabetic agents. Synthetic gliflozins show great clinical efficacy and additional beneficial effects, while also being associated with certain health risks. The plant-derived compounds seem well-tolerated but limitations due to poor bioavailability and rapid metabolism should be taken into consideration, as those pharmacokinetic barriers challenge systemic therapeutic effects. Moreover, the lack of clear in vivo evidence for direct SGLT1/2 inhibition, together with the absence of clinical studies, stand out as a major gap that requires subsequent research investigation.
Future studies should focus on clarifying the molecular interactions between natural stilbenoids and SGLT transporters in order to establish a better understanding of their mechanistic contributions to glucose transport modulation potential.

Author Contributions

Conceptualization, D.P.M., A.D.G. and E.D.; methodology, D.P.M., A.D.G. and E.D.; validation, I.H., A.S. and E.D.; investigation, D.P.M.; data curation, D.P.M., A.D.G., I.H., L.C. and E.D.; writing—original draft preparation, D.P.M.; writing—review and editing, D.P.M., A.D.G. and L.C.; visualization, A.S. and K.I.; supervision, project administration K.I. and E.D. All authors have read and agreed to the published version of the manuscript.

Funding

The publication of the present paper was supported by the University of Life Sciences “King Mihai I” from Timișoara, Romania.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study.

Acknowledgments

During the preparation of this manuscript, the authors used Windows AI-Assistant Copilot for text summarization, semantic mapping, and cross-study synthesis. All interpretations and final content were carefully reviewed and validated by the authors to ensure accuracy and scientific rigor. Zotero was employed during the preparation of the manuscript to ensure accurate and consistent in-text citation of all referenced sources.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
SGLT1sodium dependent glucose active transporter 1
SGLT2sodium dependent glucose active transporter 2
Imaxmaximum current
Qmaxpre-steady-state currents
Kmglucose concentration at which the transport velocity is one-half its maximal value
IC50half maximal inhibitory concentration
EC50concentration at which the drug reaches 50% of its maximal biological effect
AMP adenosine monophosphate
AMPKadenosine monophosphate activated protein kinase
Kiinhibition constant

References

  1. Heinemann, L. Diabetes Technology and Pets: A Market of the Future? J. Diabetes Sci. Technol. 2024, 18, 255–256. [Google Scholar] [CrossRef] [Scilit]
  2. International Diabetes Federation. Europe Diabetes Regional Report 2000–2050. 17 June 2025. Available online: https://diabetesatlas.org/data-by-location/region/europe/ (accessed on 15 June 2025).
  3. Gheibi, S.; Kashfi, K.; Ghasemi, A. A practical guide for induction of type-2 diabetes in rat: Incorporating a high-fat diet and streptozotocin. Biomed. Pharmacother. 2017, 95, 605–613. [Google Scholar] [CrossRef] [Scilit]
  4. Saunders, J. Diabetes Mellitus: In Dogs and Cats. Vet. Nurs. J. 1999, 14, 227–230. [Google Scholar] [CrossRef] [Scilit]
  5. Rieg, T.; Vallon, V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia 2018, 61, 2079–2086. [Google Scholar] [CrossRef] [Scilit]
  6. Cefalo, C.M.A.; Cinti, F.; Moffa, S.; Impronta, F.; Sorice, G.P.; Mezza, T.; Pontecorvi, A.; Giaccari, A. Sotagliflozin, the first dual SGLT inhibitor: Current outlook and perspectives. Cardiovasc. Diabetol. 2019, 18, 20. [Google Scholar] [CrossRef] [Scilit]
  7. Powell, D.R.; Zambrowicz, B.; Morrow, L.; Beysen, C.; Hompesch, M.; Turner, S.; Hellerstein, M.; Banks, P.; Strumph, P.; Lapuerta, P. Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption. J. Clin. Endocrinol. Metab. 2020, 105, e1235–e1249. [Google Scholar] [CrossRef] [Scilit]
  8. Mulani, S.Y.; Khan, S.A.; Shaikh, D.A. An Overview of Sotagliflozin: Drug Profiling and Applications as a Dual SGLT1/SGLT2 Inhibitor for Type-1 and Type-2 Diabetes Mellitus and Heart Failure. Int. Res. J. Pharm. Med. Sci. 2025, 8, 56–58. [Google Scholar]
  9. Bauer, I.; Rimbach, G.; Cordeiro, S.; Bosy-Westphal, A.; Weghuber, J.; Ipharraguerre, I.R.; Lüersen, K. A comprehensive in-vitro/in-vivo screening toolbox for the elucidation of glucose homeostasis modulating properties of plant extracts (from roots) and its bioactives. Front. Pharmacol. 2024, 15, 1396292. [Google Scholar] [CrossRef] [Scilit]
  10. Klinger, S.; Lange, P.; Brandt, E.; Hustedt, K.; Schröder, B.; Breves, G.; Herrmann, J. Degree of SGLT1 phosphorylation is associated with but does not determine segment-specific glucose transport features in the porcine small intestines. Physiol. Rep. 2018, 6, e13562. [Google Scholar] [CrossRef] [Scilit]
  11. Fuloria, S.; Sekar, M.; Khattulanuar, F.S.; Gan, S.H.; Rani, N.N.I.M.; Ravi, S.; Subramaniyan, V.; Jeyabalan, S.; Begum, M.Y.; Chidambaram, K.; et al. Chemistry, Biosynthesis and Pharmacology of Viniferin: Potential Resveratrol-Derived Molecules for New Drug Discovery, Development and Therapy. Molecules 2022, 27, 5072. [Google Scholar] [CrossRef] [Scilit]
  12. Hidalgo, J.; Teuber, S.; Morera, F.; Ojeda, C.; Flores, C.A.; Hidalgo, M.A.; Núñez, L.; Villalobos, C.; Burgos, R.A. Delphinidin Reduces Glucose Uptake in Mice Jejunal Tissue and Human Intestinal Cells Lines through FFA1/GPR40. Int. J. Mol. Sci. 2017, 18, 750. [Google Scholar] [CrossRef] [Scilit]
  13. Gómez-Zorita, S.; Milton-Laskibar, I.; Eseberri, I.; Beaumont, P.; Courtois, A.; Krisa, S.; Portillo, M.P. Beneficial Effects of ε-Viniferin on Obesity and Related Health Alterations. Nutrients 2023, 15, 928. [Google Scholar] [CrossRef] [Scilit]
  14. Fernandes, J.C.; Schemitt, E.G.; Da Silva, J.; Marroni, N.P.; Lima, A.; Ferreira, R.B. Combination of Trans-Resveratrol and ε-Viniferin Induces a Hepatoprotective Effect in Rats with Severe Acute Liver Failure via Reduction of Oxidative Stress and MMP-9 Expression. Nutrients 2021, 13, 3677. [Google Scholar] [CrossRef] [Scilit]
  15. Wright, E.M.; Loo, D.D.F.; Hirayama, B.A.; Turk, E. Surprising Versatility of Na+-Glucose Cotransporters: SLC5. Physiology 2004, 19, 370–376. [Google Scholar] [CrossRef] [Scilit]
  16. Sędzikowska, A.; Szablewski, L. Human Glucose Transporters in Renal Glucose Homeostasis. Int. J. Mol. Sci. 2021, 22, 13522. [Google Scholar] [CrossRef] [Scilit]
  17. Sabino-Silva, R.; Mori, R.C.; David-Silva, A.; Okamoto, M.M.; Freitas, H.S.; Machado, U.F. The Na+/glucose cotransporters: From genes to therapy. Braz. J. Med. Biol. Res. 2010, 43, 1019–1026. [Google Scholar] [CrossRef] [Scilit]
  18. Dyer, J.; Vayro, S.; King, T.P.; Shirazi-Beechey, S.P. Glucose sensing in the intestinal epithelium. Eur. J. Biochem. 2003, 270, 3377–3388. [Google Scholar] [CrossRef] [Scilit]
  19. Stearns, A.T.; Balakrishnan, A.; Rhoads, D.B.; Tavakkolizadeh, A. Rapid Upregulation of Sodium-Glucose Transporter SGLT1 in Response to Intestinal Sweet Taste Stimulation. Ann. Surg. 2010, 251, 865–871. [Google Scholar] [CrossRef] [Scilit]
  20. Solberg, D.H.; Diamond, J.M. Comparison of different dietary sugars as inducers of intestinal sugar transporters. Am. J. Physiol.-Gastrointest. Liver Physiol. 1987, 252, G574–G584. [Google Scholar] [CrossRef] [Scilit]
  21. Nakamura, C.; Ishizuka, N.; Yokoyama, K.; Yazaki, Y.; Tatsumi, F.; Ikumi, N.; Hempstock, W.; Ikari, A.; Yoshino, Y.; Hayashi, H. Regulatory mechanisms of glucose absorption in the mouse proximal small intestine during fasting and feeding. Sci. Rep. 2023, 13, 10838. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Klinger, S.; Breves, G. Resveratrol Inhibits Porcine Intestinal Glucose and Alanine Transport: Potential Roles of Na+/K+-ATPase Activity, Protein Kinase A, AMP-Activated Protein Kinase and the Association of Selected Nutrient Transport Proteins with Detergent Resistant Membranes. Nutrients 2018, 10, 302. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Koepsell, H. Glucose transporters in the small intestine in health and disease. Pflügers Arch.-Eur. J. Physiol. 2020, 472, 1207–1248. [Google Scholar] [CrossRef] [Scilit]
  24. Han, L.; Qu, Q.; Aydin, D.; Panova, O.; Robertson, M.J.; Xu, Y.; Dror, R.O.; Skiniotis, G.; Feng, L. Structure and mechanism of the SGLT family of glucose transporters. Nature 2022, 601, 274–279. [Google Scholar] [CrossRef] [Scilit]
  25. Merino, B.; Fernández-Díaz, C.M.; Cózar-Castellano, I.; Perdomo, G. Intestinal Fructose and Glucose Metabolism in Health and Disease. Nutrients 2019, 12, 94. [Google Scholar] [CrossRef] [Scilit]
  26. Loo, D.D.F.; Hirayama, B.A.; Meinild, A.; Chandy, G.; Zeuthen, T.; Wright, E.M. Passive water and ion transport by cotransporters. J. Physiol. 1999, 518, 195–202. [Google Scholar] [CrossRef] [Scilit]
  27. Panayotova-Heiermann, M.; Wright, E.M. Mapping the urea channel through the rabbit Na+-glucose cotransporter SGLT1. J. Physiol. 2001, 535, 419–425. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  28. Ghezzi, C.; Loo, D.D.F.; Wright, E.M. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia 2018, 61, 2087–2097. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Pontoglio, M.; Prié, D.; Cheret, C.; Doyen, A.; Leroy, C.; Froguel, P.; Velho, G.; Yaniv, M.; Friedlander, G. HNF1α controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000, 1, 359–365. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Freitas, H.S.; Anhê, G.F.; Melo, K.F.S.; Okamoto, M.M.; Oliveira-Souza, M.; Bordin, S.; Machado, U.F. Na+-Glucose Transporter-2 Messenger Ribonucleic Acid Expression in Kidney of Diabetic Rats Correlates with Glycemic Levels: Involvement of Hepatocyte Nuclear Factor-1α Expression and Activity. Endocrinology 2008, 149, 717–724. [Google Scholar] [CrossRef] [Scilit]
  31. Hiraizumi, M.; Akashi, T.; Murasaki, K.; Kishida, H.; Kumanomidou, T.; Torimoto, N.; Nureki, O.; Miyaguchi, I. Transport and inhibition mechanism of the human SGLT2–MAP17 glucose transporter. Nat. Struct. Mol. Biol. 2024, 31, 159–169. [Google Scholar] [CrossRef] [Scilit]
  32. Hummel, C.S.; Lu, C.; Loo, D.D.F.; Hirayama, B.A.; Voss, A.A.; Wright, E.M. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am. J. Physiol. Cell Physiol. 2011, 300, C14–C21. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Borah, A.K.; Ahmed, S.A.; Borah, J.C. Phytomedicine as a source of SGLT2 inhibitors, GLP-1 secretagogues and DPP-IV inhibitors for mitigation of Diabetic Nephropathy. Phytomed. Plus 2022, 2, 100225. [Google Scholar] [CrossRef] [Scilit]
  34. Raja, M.; Puntheeranurak, T.; Gruber, H.J.; Hinterdorfer, P.; Kinne, R.K.H. The role of transporter ectodomains in drug recognition and binding: Phlorizin and the sodium–glucose cotransporter. Med. Chem. Commun. 2016, 7, 1056–1068. [Google Scholar] [CrossRef] [Scilit]
  35. Zeuthen, T.; Gorraitz, E.; Her, K.; Wright, E.M.; Loo, D.D.F. Structural and functional significance of water permeation through cotransporters. Proc. Natl. Acad. Sci. USA 2016, 113, E6887–E6894. [Google Scholar] [CrossRef] [Scilit]
  36. Azizogli, A.; Vitti, M.R.; Mishra, R.; Osorno, L.; Heffernan, C.; Kumar, V.A. Comparison of SGLT1, SGLT2, and Dual Inhibitor Biological Activity in Treating Type 2 Diabetes Mellitus. Adv. Ther. 2023, 6, 2300143. [Google Scholar] [CrossRef] [Scilit]
  37. Selleck Biotechnology GmbH. SGLT Inhibitors. Available online: https://www.selleckchem.com/SGLT.html (accessed on 2 February 2026).
  38. Meng, W.; Ellsworth, B.A.; Nirschl, A.A.; McCann, P.J.; Patel, M.; Girotra, R.N.; Wu, G.; Sher, P.M.; Morrison, E.P.; Biller, S.A.; et al. Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes. J. Med. Chem. 2008, 51, 1145–1149. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  39. Thomas, L.; Grempler, R.; Eckhardt, M.; Himmelsbach, F.; Sauer, A.; Klein, T.; Eickelmann, P.; Mark, M. Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats. Diabetes Obes. Metab. 2012, 14, 94–96. [Google Scholar] [CrossRef] [Scilit]
  40. Courtois, A.; Atgié, C.; Marchal, A.; Hornedo-Ortega, R.; Lapèze, C.; Faure, C.; Richard, T.; Krisa, S. Tissular Distribution and Metabolism of trans-ε-Viniferin after Intraperitoneal Injection in Rat. Nutrients 2018, 10, 1660. [Google Scholar] [CrossRef] [Scilit]
  41. Ohara, K.; Kusano, K.; Kitao, S.; Yanai, T.; Takata, R.; Kanauchi, O. ε-Viniferin, a resveratrol dimer, prevents diet-induced obesity in mice. Biochem. Biophys. Res. Commun. 2015, 468, 877–882. [Google Scholar] [CrossRef] [Scilit]
  42. Zhou, F.; Du, N.; Zhou, L.; Wang, C.; Ren, H.; Sun, Q. The safety of sotagliflozin in the therapy of diabetes mellitus type 1 and type 2: A meta-analysis of randomized trials. Front. Endocrinol. 2022, 13, 968478. [Google Scholar] [CrossRef] [Scilit]
  43. Blaschek, W. Natural Products as Lead Compounds for Sodium Glucose Cotransporter (SGLT) Inhibitors. Planta Med. 2017, 83, 985–993. [Google Scholar] [CrossRef] [Scilit]
  44. Sotagliflozin. Available online: https://go.drugbank.com/drugs/DB12713 (accessed on 7 August 2025).
  45. Pelletier, R.; Ng, K.; Alkabbani, W.; Labib, Y.; Mourad, N.; Gamble, J.M. Adverse events associated with sodium glucose co-transporter 2 inhibitors: An overview of quantitative systematic reviews. Ther. Adv. Drug Saf. 2021, 12, 1–15. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Rizvi, S.; Shakil, S.; Biswas, D.; Shaikh, S.; Bagga, P.; Kamal, M.A. Invokana (Canagliflozin) as a Dual Inhibitor of Acetylcholinesterase and Sodium Glucose Co-Transporter 2: Advancement in Alzheimer’s Disease-Diabetes Type 2 Linkage via an Enzoinformatics Study. CNS Neurol. Disord.-Drug Targets 2014, 13, 447–451. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  47. Liu, R.; Zhang, Y.; Yao, X.; Wu, Q.; Wei, M.; Yan, Z. ε-Viniferin, a promising natural oligostilbene, ameliorates hyperglycemia and hyperlipidemia by activating AMPK in vivo. Food Funct. 2020, 11, 10084–10093. [Google Scholar] [CrossRef] [Scilit]
  48. Gambini, J.; Inglés, M.; Olaso, G.; Lopez-Grueso, R.; Bonet-Costa, V.; Gimeno-Mallench, L.; Mas-Bargues, C.; Abdelaziz, K.M.; Gomez-Cabrera, M.C.; Vina, J.; et al. Properties of Resveratrol: In Vitro and In Vivo Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxidative Med. Cell. Longev. 2015, 2015, 37042. [Google Scholar] [CrossRef] [Scilit]
  49. Arts, I.C.W.; Sesink, A.L.A.; Hollman, P.C.H. Quercetin-3-Glucoside Is Transported by the Glucose Carrier SGLT1 across the Brush Border Membrane of Rat Small Intestine. J. Nutr. 2002, 132, 2823. [Google Scholar] [CrossRef] [Scilit]
  50. Schloesser, A.; Esatbeyoglu, T.; Schultheiß, G.; Vollert, H.; Lüersen, K.; Fischer, A.; Rimbach, G. Antidiabetic Properties of an Apple/Kale Extract In Vitro, In Situ, and in Mice Fed a Western-Type Diet. J. Med. Food 2017, 20, 846–854. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  51. Shriwas, P.; Chen, X.; Kinghorn, A.D.; Ren, Y. Plant-derived glucose transport inhibitors with potential antitumor activity. Phytother. Res. 2020, 34, 1027–1040. [Google Scholar] [CrossRef] [Scilit]
  52. Guschlbauer, M.; Klinger, S.; Burmester, M.; Horn, J.; Kulling, S.E.; Breves, G. trans-Resveratrol and ε-viniferin decrease glucose absorption in porcine jejunum and ileum in vitro. Comp. Biochem. Physiol. Part A Mol. Integr. Physiol. 2013, 165, 313–318. [Google Scholar] [CrossRef] [Scilit]
  53. Mattio, L.M.; Marengo, M.; Parravicini, C.; Eberini, I.; Dallavalle, S.; Bonomi, F.; Iametti, S.; Pinto, A. Inhibition of Pancreatic α-amylase by Resveratrol Derivatives: Biological Activity and Molecular Modelling Evidence for Cooperativity between Viniferin Enantiomers. Molecules 2019, 24, 3225. [Google Scholar] [CrossRef] [Scilit]
  54. Schulze, C. From Molecule to Men: Inhibition of Intestinal Glucose Absorption by Polyphenols and Plant Extracts for Reducing the Glycemic Response. Ph.D. Thesis, Technische Universität München, Munich, Germany, 2014. [Google Scholar]
  55. Beaumont, P.P. L’ε-Viniférine, Un Dimère Du Resvératrol: Encapsulation, Métabolisme et Propriétés Biologiques. Biochimie, Biologie Moléculaire. Doctoral Thesis, Université de Bordeaux, Bordeaux, France, 2021. Available online: https://theses.hal.science/tel-03499885v1 (accessed on 15 September 2025).
  56. Ohgaki, R.; Wei, L.; Yamada, K.; Hara, T.; Kuriyama, C.; Okuda, S.; Ueta, K.; Shiotani, M.; Nagamori, S.; Kanai, Y. Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features. J. Pharmacol. Exp. Ther. 2016, 358, 94–102. [Google Scholar] [CrossRef] [Scilit]
  57. Grempler, R.; Thomas, L.; Eckhardt, M.; Himmelsbach, F.; Sauer, A.; Sharp, D.E.; Bakker, R.A.; Mark, M.; Klein, T.; Eickelmann, P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 2012, 14, 83–90. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. Oranje, P.; Gouka, R.; Burggraaff, L.; Vermeer, M.; Chalet, C.; Duchateau, G.; van der Pijl, P.; Geldof, M.; de Roo, N.; Clauwaert, F.; et al. Novel natural and synthetic inhibitors of solute carriers SGLT1 and SGLT2. Pharmacol. Res. Perspect. 2019, 7, e00504. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  59. Saad, N.M.; Sekar, M.; Gan, S.H.; Lum, P.T.; Vaijanathappa, J.; Ravi, S. Resveratrol: Latest Scientific Evidences of its Chemical, Biological Activities and Therapeutic Potentials. Pharmacogn. J. 2020, 12, 1779–1791. [Google Scholar] [CrossRef] [Scilit]
  60. Selvaraj, S.; Mohan, A.; Narayanan, S.; Sethuraman, S.; Krishnan, U.M. Dose-Dependent Interaction of trans-Resveratrol with Biomembranes: Effects on Antioxidant Property. J. Med. Chem. 2013, 56, 970–981. [Google Scholar] [CrossRef] [Scilit]
  61. Fei, Q.; Kent, D.; Botello-Smith, W.M.; Nur, F.; Nur, S.; Alsamarah, A.; Chatterjee, P.; Lambros, M.; Luo, Y. Molecular Mechanism of Resveratrol’s Lipid Membrane Protection. Sci. Rep. 2018, 8, 1587. [Google Scholar] [CrossRef] [Scilit]
  62. Delmas, D.; Aires, V.; Limagne, E.; Dutartre, P.; Mazue, F.; Ghiringhelli, F.; Latruffe, N. Transport, stability, and biological activity of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215, 48–59. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Chen, M.L.; Yi, L.; Jin, X.; Xie, Q.; Zhang, T.; Zhou, X.; Chang, H.; Fu, Y.-J.; Zhu, J.-D.; Zhang, Q.-Y.; et al. Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway. J. Nutr. Biochem. 2013, 24, 1823–1829. [Google Scholar] [CrossRef] [Scilit]
  64. Peng, J.; Lu, C.; Luo, Y.; Su, X.; Li, S.; Ho, C.T. Hypoglycemic effects and associated mechanisms of resveratrol and related stilbenes in diet. Food Funct. 2024, 15, 2381–2405. [Google Scholar] [CrossRef] [Scilit]
  65. Pébarthé-Courrouilh, A.; Jaa, A.; Valls-Fonayet, J.; Da Costa, G.; Palos-Pinto, A.; Richard, T.; Cluzet, S. UV-exposure decreases antimicrobial activities of a grapevine cane extract against Plasmopara viticola and Botrytis cinerea as a consequence of stilbene modifications—A kinetic study. Pest Manag. Sci. 2024, 80, 6389–6399. [Google Scholar] [CrossRef] [Scilit]
  66. Alafnan, A. Biochemical Interaction Analysis of Natural SGLT2 Inhibitors with Alzheimer Targets: A Computational Approach. J. Biochem. Technol. 2020, 11, 73–84. [Google Scholar] [CrossRef] [Scilit]
  67. Chen, L.; Tuo, B.; Dong, H. Regulation of Intestinal Glucose Absorption by Ion Channels and Transporters. Nutrients 2016, 8, 43. [Google Scholar] [CrossRef] [Scilit]
  68. Beaumont, P.; Faure, C.; Courtois, A.; Jourdes, M.; Marchal, A.; Teissedre, P.-L.; Richard, T.; Atgié, C.; Krisa, S. Trans-ε-Viniferin Encapsulation in Multi-Lamellar Liposomes: Consequences on Pharmacokinetic Parameters, Biodistribution and Glucuronide Formation in Rats. Nutrients 2021, 13, 4212. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Journal Statistics
Multiple requests from the same IP address are counted as one view.
The FAM111A Gene: Genetic, Epigenetic, and Pharmacological Targets and Mechanistic Insights with Clinical Relevance
Previous
KRDQN: An Interpretable Prediction Framework for Adverse Drug Reactions via Knowledge–Graph Reinforced Deep Q-Learning
Next